|Mr. Umang Vohra||MD, Global CEO & Exec. Director||135.6M||N/A||1971|
|Ms. Samina Hamied||Exec. Vice-Chairperson||67.5M||N/A||1976|
|Mr. Kedar Upadhye CS, MBA||Global Chief Financial Officer||26.5M||N/A||1977|
|Mr. Rajendra Chopra||Compliance Officer & Company Sec.||15.3M||N/A||N/A|
|Dr. Raju Sunil Mistry M.A., Ph.D.||Pres & Global Chief People Officer||N/A||N/A||1965|
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other dosage forms consists of injectables and biosimilars. The company has collaboration with CSIR-Indian Institute of Chemical Technology for the development of medication for the treatment of COVID-19. Cipla Limited was founded in 1935 and is headquartered in Mumbai, India.
Cipla Limited’s ISS governance QualityScore as of 8 December 2019 is 7. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 8; Compensation: 9.